BACS™ Microbubbles: The Solution to Better Cell Separation
21 December 2022
In this interview, Brandon McNaughton, CEO and Co-Founder of Akadeum Life Sciences, explains the story of innovation for the application of microbubbles in cell therapy manufacturing, and the impact innovation can have on the future of healthcare.
Through explaining the story behind Akadeum and the application of innovative technologies, Brandon discusses the process of overcoming limitations and challenges associated with downstream cell therapy manufacturing.
Brandon goes on to discuss the process of deployment through collaboration, before explaining what it is companies like Akadeum look for in a partner, and what to look out from Akadeum over the next few months.
If you are joining us at Advanced Therapies Week 2023, make sure to visit Akadeum as the team previews their new automated instrument! Not yet registered? Get your tickets here >>
This interview has been produced in partnership with Akadeum Life Sciences, ahead of Advanced Therapies Week 2023.
More like this
Gilead’s Yescarta Demonstrates Improvement in Overall Survival for Aggressive Blood Cancers
Kite’s Yescarta CAR-T cell therapy has demonstrated significant improvement for the treatment of relapsed/refractory large B-cell lymphoma from its Phase III ZUMA trial.
23 March 2023
Pfizer Invests $43 Billion to Acquire Seagen
Pfizer is to acquire global technology company Seagan in a definitive merger agreement for a total enterprise value of $43 billion.
14 March 2023
Early Adoption and Partnerships – The Secret to Commercialization Success?
This Briefing from Advanced Therapies Week 2023 focusses on how partnerships within the industry can advance research from the clinic to manufacturing scale, to keep pace with the evolving field.
2 March 2023